Fees for Blood and Its Components in 2027 – New Rates from January 1
From the beginning of next year, healthcare facilities will pay new rates, set by the Ministry of Health, for blood and its components supplied by the public blood service.

National Cancer Institute · Unsplash License
- 0views
- 0likes and saves
- 0skips
In brief
- A Regulation of the Minister of Health sets the fees for blood and its components supplied by the public blood service in 2027.
- The highest rate applies to a therapeutic dose of apheresis platelet concentrate with reduced leukocytes, PLN 1265.00.
- The new amounts apply from 1 January 2027.
New rates for 2027
On 6 November 2026, the Minister of Health signed a regulation specifying how much healthcare facilities will pay in 2027 for blood and its components obtained from the public blood service (Regulation of the Minister of Health of 6 November 2026 on determining the amount of fees for blood and its components in 2027 – Dziennik Ustaw RP). The act was published on 16 November 2026 and will enter into force on 1 January 2027..
What facilities will pay for individual products
The most expensive item is a therapeutic dose of apheresis platelet concentrate with reduced leukocytes, priced at PLN 1265.00. A unit of granulocyte concentrate costs PLN 1677.00. Preserved whole blood costs PLN 368.00, and red blood cell concentrate from whole blood PLN 247.00. Red blood cell concentrate from apheresis is priced at PLN 351.00.
Fresh frozen plasma costs PLN 133.00 per unit, and cryoprecipitate PLN 260.00. Platelets from whole blood, in the form of a therapeutic dose, are to cost PLN 654.00.
Who the new fees apply to
The new amounts apply to blood and components supplied by units of the public blood service listed in the Act on the Public Blood Service. The basis for issuing the regulation is the authorization contained in that Act.
What comes next
From 1 January 2027, the new amounts will apply when blood and its components are issued. Facilities and patients using these products should take them into account when planning treatment costs.
Sources
Discussion0
- No comments from this perspective yet. Be the first.